SMO and pachyonychia congenita: Vismodegib, an SMO antagonist, was evaluated in combination with gemcitabine in a phase Ib/II trial, enrolling 106 previously untreated PC patients, yet failing to improve the outcomes of the chemotherapeutic agent compared with placebo [83].